Zydus Lifesciences has informed that, Sentynl Therapeutics Inc., USA, a wholly owned subsidiary (‘Sentynl’) of the Company has acquired worldwide proprietary rights to Zokinvy® (lonafarnib) from Eiger Biopharmaceuticals Inc., USA (‘Seller’), pursuant to an asset purchase agreement (‘APA’), adding to portfolio of biopharmaceuticals for rare and ultra-rare diseases. Zokinvy® is approved in the U.S. (2020), European Union and Great Britain (2022), and Japan (2024) for the treatment of Progeria, a collection of ultra-rare, fatal, genetic premature aging diseases that accelerate mortality in young patients. Necessary details as stipulated under regulation 30 of the Listing Regulations read with para 5 of Part II of the SEBI Circular dated July 13, 2023 are provided in Annexure- ‘1’.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: